China Resources Double-Crane Pharmaceutical Co Ltd (SHG:600062) — Market Cap & Net Worth

$2.55 Billion USD · CN¥17.41 Billion CNY · Rank #5522

Market Cap & Net Worth: China Resources Double-Crane Pharmaceutical Co Ltd (600062)

China Resources Double-Crane Pharmaceutical Co Ltd (SHG:600062) has a market capitalization of $2.55 Billion (CN¥17.41 Billion) as of June 17, 2026. Listed on the SHG stock exchange, this China-based company holds position #5522 globally and #1075 in its home market, demonstrating a 0.30% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Resources Double-Crane Pharmaceutical Co Ltd's stock price CN¥16.76 by its total outstanding shares 1038757509 (1.04 Billion). Review 600062 total debt and obligations to assess the company's total debt and financial obligations.

China Resources Double-Crane Pharmaceutical Co Ltd Market Cap History: 2015 to 2026

China Resources Double-Crane Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $2.08 Billion to $2.55 Billion (2.01% CAGR).

Index Memberships

China Resources Double-Crane Pharmaceutical Co Ltd is a constituent of 1 market index:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
Shanghai Shenzhen CSI 300 CSI300	$3.93 Trillion	0.06%	#188 of 285

Weight: China Resources Double-Crane Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

China Resources Double-Crane Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how China Resources Double-Crane Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

0.27x

China Resources Double-Crane Pharmaceutical Co Ltd's market cap is 0.27 times its annual revenue

Industry average: 0.53x Lower than industry average

Latest Price to Earnings (P/E) Ratio

1.85x

China Resources Double-Crane Pharmaceutical Co Ltd's market cap is 1.85 times its annual earnings

Industry average: 0.02x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2015	$2.08 Billion	$5.14 Billion	$661.06 Million	0.41x	3.15x
2016	$2.05 Billion	$5.49 Billion	$714.21 Million	0.37x	2.87x
2017	$2.75 Billion	$6.42 Billion	$842.61 Million	0.43x	3.26x
2018	$1.62 Billion	$8.23 Billion	$968.59 Million	0.20x	1.67x
2019	$1.79 Billion	$9.38 Billion	$1.06 Billion	0.19x	1.69x
2020	$1.68 Billion	$8.50 Billion	$1.01 Billion	0.20x	1.67x
2021	$1.92 Billion	$9.11 Billion	$935.69 Million	0.21x	2.05x
2022	$2.67 Billion	$9.63 Billion	$1.18 Billion	0.28x	2.27x
2023	$2.83 Billion	$11.31 Billion	$1.67 Billion	0.25x	1.69x
2024	$3.01 Billion	$11.21 Billion	$1.63 Billion	0.27x	1.85x

Competitor Companies of 600062 by Market Capitalization

Companies near China Resources Double-Crane Pharmaceutical Co Ltd in the global market cap rankings as of June 17, 2026.

Key companies related to China Resources Double-Crane Pharmaceutical Co Ltd by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#513	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#561	GALDERMA GROUP AG	NYSE:GALDY	$48.78 Billion	$43.22
#624	Jiangsu Hengrui Medicine Co Ltd	SHG:600276	$44.20 Billion	CN¥47.35
#635	Takeda Pharmaceutical Company Limited	F:TKDA	$43.60 Billion	€13.60

China Resources Double-Crane Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, China Resources Double-Crane Pharmaceutical Co Ltd's market cap moved from $2.08 Billion to $ 2.55 Billion, with a yearly change of 2.01%.

Year	Market Cap	Change (%)
2026	CN¥2.55 Billion	-8.37%
2025	CN¥2.78 Billion	-7.63%
2024	CN¥3.01 Billion	+6.45%
2023	CN¥2.83 Billion	+5.76%
2022	CN¥2.67 Billion	+39.26%
2021	CN¥1.92 Billion	+14.33%
2020	CN¥1.68 Billion	-6.04%
2019	CN¥1.79 Billion	+10.28%
2018	CN¥1.62 Billion	-41.07%
2017	CN¥2.75 Billion	+34.23%
2016	CN¥2.05 Billion	-1.63%
2015	CN¥2.08 Billion	--

End of Day Market Cap According to Different Sources

On Jun 17th, 2026 the market cap of China Resources Double-Crane Pharmaceutical Co Ltd was reported to be:

Source	Market Cap
Yahoo Finance	$2.55 Billion USD
MoneyControl	$2.55 Billion USD
MarketWatch	$2.55 Billion USD
marketcap.company	$2.55 Billion USD
Reuters	$2.55 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About China Resources Double-Crane Pharmaceutical Co Ltd

SHG:600062 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.55 Billion

CN¥17.41 Billion CNY

Market Cap Rank

#5522 Global

#1075 in China

Share Price

CN¥16.76

Change (1 day)

-1.64%

52-Week Range

CN¥16.50 - CN¥21.22

All Time High

CN¥33.06